#pharma companies in Ireland | Explore Tumblr posts and blogs

bootleg-nessie · 1 year ago

Text

Things that will happen in the future (based on my own experiences with time travel):

***FAQs at the end***

*All of these observations are copied directly from my notes in roughly the order I took them in

*Don’t ask about the interchanging use of past/present/future tense, you know how that stuff is with time travel

Women just started all growing three boobs instead of two. Scientists baffled

Genetically engineered catboys (no literally)

The great pyramid of Giza has been converted into a Bass Pro Shop

The entire state of Rhode Island was bought by some rich tech CEO who promptly dug a 500 foot wide trench around the entire state so that it could in fact be an island. It was soon converted into the world’s largest parking lot

Pollution has gotten so bad that fresh oxygen is now delivered straight to most homes via a subscription service

Basic necessities such as food, water, and housing are now provided for free by the government, but only for the top 1% of wealth holders

Insulin now costs twice as much as rent. “Get fucked,” say pharma companies

92.6% of new electronic appliances now have smartphone integration and require a monthly subscription to use

Most billionaires have real estate on earth’s moon

As an ongoing film experiment, Taika Waititi successfully convinced a Nebraska man that he’s been raptured and is now in heaven. He actually got Truman Show��d and now millions of viewers tune in every week to watch God (played by John DiMaggio) manipulate Robert into confronting his own views, battle cognitive dissonance, and face the realization that he might not have been as good of a person on Earth as he thought he was

Carrots have gone extinct, as have highland cows

Species of extinct animals and plants now are being posthumously renamed after the billionaires and elites most directly responsible for killing then off

Researchers discovered a sentient colony of fungus off the coast of Chile, it prefers to go by Fleebo and appears to have a incredibly complex intelligence far greater than any other observed organic being

Nobody knows where Ireland went. It literally just disappeared off the face of the earth one day and nobody bothered to question it. The story couldn’t compete in the news cycle with the recent news about a company in China that made the first real life pokemon. An entire civilization of people gone and I’m the only one who seems to remember it or even care

Fleebo and its offspring have annexed Madagascar and are threatening any retaliation with nuclear warfare and “making The Last of Us a reality.” Nobody knows if Fleebo actually has the capabilities to do this, but after the Lovecraft incident we’re all TOO goddam scared to fuck around and find out

Large snails have replaced cats and dogs as the most common household pet. Snail culture has largely taken over the world, especially Japan

The president of the United States is now decided with an oiled up twerking competition. Most people were hesitant at first but this has produced vastly more competent leaders so now everyone just kinda goes along with it

With the cost of living crisis only worsening with time, selling tattoo space on your body to advertisers has become common as people struggle to afford rent and pay their bills

North and South Korea have reunited into “Korea 2.0”

Germany has split up into East and West Germany again

Belgium and France have been annexed by West Germany and renamed “Wester Germany” and “Westest Germany” respectively

The entirety of Florida is now underwater. Most of Kansas is too for some reason that scientists refuse to explain because they’ve “sworn an oath to the eldritch gods” and that “much worse things would happen” if they did

The melting ice caps in Antarctica unveiled a lost civilization of intelligent creatures descended from a species of lungfish, predating human civilization by millions of years. They planned on hibernating for another 10-15 million years to observe the course of evolution on Earth and are very very angry at humans for waking them up prematurely and ruining all of that with global warming

The politically correct term for lungfish people is “Dipnoid” but most people refer to them by a variety of slurs, such as “finwalker” and “kelp muncher” (not that they even eat kelp)

The Great Pacific Garbage Patch has now increased to nearly half the size of what was formerly known as Canada and has been colonized entirely by pirates (the flag is actually pretty cool). The pirate nation has the 17th largest economy in the world and is projected to surpass the United States in GDP

Africa is about 2% smaller. Nobody knows why. Most people point to Fleebo, who denies having any involvement

All human-Dipnoid interaction was promptly banned by most world governments, except for the GPGPRP (Great Pacific Garbage Patch Republic of Pirates), whom the Dipnoids rely upon extensively for trade

Scientists have used DNA from fossils to recreate other species of humans. We now live alongside them like we did for thousands of years before everyone besides Homo sapiens went extinct. Racism is at an all time high

Class C and above robots are now legally recognized by most progressive countries as people

The United States government has been exposed for secretly funneling billions of dollars into the GPGPRP and using it to fund terrorist operations all over the world.

A new major religion revolving around Dave Grohl has skyrocketed in popularity. Grohilsm is now the world’s largest religion, second only to Fleeboism

Scientists discovered a new continent in the Pacific Ocean, and then promptly lost it again. Most people are convinced this was just an elaborate practical joke, but scientists “swear it definitely happened”

For a brief period of about 30 years, everything in George Orwell’s 1984 happened almost exactly as written in the book. Literally 1984

It was revealed that Jeff Epstein didn’t kill himself. He actually faked his death and spent the next few years in a drug-fueled episode of psychosis making sock puppets in a cave in Italy and then molesting said sock puppets until he died from a sock puppet related illness

Bigfoot was discovered off the coast of Georgia doing cocaine with a congregation of alligators. When questioned, he said he normally lives in Montana and was only there on vacation. He is now a celebrity, and has been featured in a number of tv shows and films, two of which he won an Oscar for. Last I checked, he was a washed up actor living in Hollywood with a reanimated Neanderthal woman

The GPGPRP raided most of England’s museums with the object of “doing exactly what they did for the last few centuries” England was understandably furious, but the rest of the world found it rather amusing

England declared war on the GPGPRP, which it promptly lost after hackers brought down the entire country’s military overnight. Much like in the 21st century, England is the world’s laughing stock

The entirety of Luxembourg relocated itself to the moon

Russia attempted to take over most of Eurasia. In retaliation to the full global effort to stop them, they launched nukes at the world’s 600 most populous cities outside of its current territory. Most of the warheads were stopped in time, but a few major metropolitan areas got hit pretty badly, including Los Angeles, Hong Kong, Chengdu, Mexico City, and Istanbul. Japan was understandably super pissed that Hiroshima and Nagasaki got nuked for a second time

In the wake of the nuclear holocaust, Canada assumed control over what was formerly Russia and assimilated many of its citizens and leaders into its own society and government. Under the new rule of formerly Russian leaders, Canada became a puppet state for the second coming of Russia. It annexed much of the United States, Mongolia, China, and a handful of other countries, becoming “the world’s first megacountry.” Crungolaska now controls a majority of the northern hemisphere

As part of a practical joke by Adam Sandler, Tom Hanks was actually marooned on a desert island like in Castaway. He lasted less than a week before he died. When I left this era of the future, Adam Sandler was serving a lifetime sentence in prison for murder

Fringe groups of crows with above-average intelligence have started popping up around the world. So far they have been observed forming small communities, crafting relatively complex tools, using rudimentary speech, performing rituals, and creating music

Aliens visited earth and had a formal meeting with many of our world leaders, but decided to leave us alone for a few thousand more years because humanity is “not yet mature enough to handle the responsibilities of interstellar travel.” They have incentivized us with a the blueprints for an Alcubierre Drive and a means to produce the exotic matter to fuel it once they deem us as being ready

The original colony of settlers on Mars has declared independence, officially becoming the first country not on Earth

We sent Tom Cruise back to space but this time we just left him there

The tether for the space elevator broke. The town known as Vatorville, famous for being the location of the takeoff point of the elevator shuttle on Earth, was completely decimated as tens of thousands of miles of steel cable came crashing back down. There were no survivors

Most people in first and second world countries have mandatory microchip implants that serve as a personal ID

Last Thursdayism has been largely denounced by quantum physicists. Current theories now revolve around “Next Thursdayism,” the belief that the entire universe was created in the future and that we all exist as a memory in the past

Synthetic organ farms for transplants and research have become a massive industry worth billions of dollars. However, there is still a huge black market for organically grown human organs, as they’re much cheaper to acquire and aren’t taxed at the exorbitant rates that lab-grown organs are

China dug a hole all the way to the center of the Earth. Turns out it’s hollow and there are people living inside. Who knew?

A university reconstructed the entire city of Rome as it was in its early days during the Roman Empire. It’s actually pretty historically accurate, except for the fact that there’s a lot less sex because it’s run by a bunch of sweaty history nerds

After Rome 2 resulted in the creation of a cult revolving around the Roman god of the dead that gained traction as a minor religion, Pluto was officially reinstated as a planet by NASA when cultists picketed their headquarters every day for nearly 3 years straight. “Fine, we’ll give these fucking virgins what they want so they’ll finally shut the hell up,” said NASA’s administrator in chief

In a display of the biotechnical prowess of Disney’s Imagineers, all the animatronics in Disney’s Hall of Presidents were replaced with clones of the originals, which went about exactly as well as you’d expect. After reports of the presidents hurling a series of racial slurs and other obscenities at the first black family to enter surfaced, the project was shut down almost immediately after it had opened. Minority admission to Magic Kingdom plummeted to 2.3% of its numbers from the previous year, making it the second whitest place on earth after a taylor swift concert

Plastic now makes up about 3% of every organism on earth by weight

Public officials are now required by law to take shrooms before running for office

Trees are considered a rare and highly sought after commodity, and are usually only owned by public institutions and the rich (the vast majority of oxygen farms use algae to produce oxygen)

FAQs:

FAQ: What time period(s) did you go to?

A: I have no fucking clue. The world stopped using the Gregorian calendar in 2063 after a gamma ray burst hit the sun. The GRB led to stellar ablation, which changed the length of a year on Earth. The sun would continue to lose mass at an accelerated rate for several more years, with the length of the year changing slightly from year to year. The world adopted a variety of different calendars which kept being updated frequently and were often super confusing and contradictory. I traveled to about a dozen different points in time, which based on my best estimates spanned within a few millennia of the current date.

FAQ: How did you obtain a time machine?

A: I think it was the 17th or 18th of June, 2055? That night, a large sci-fi looking box thingy roughly the size of a VW Bus appeared a few hundred yards away in the open field in front of my house. I tried to take a picture of the box, but for some reason the closer I got, the more the image on my camera started to become fuzzy, and by the time I got close enough to take a decent picture, the camera had stopped working altogether. I pulled open a door to reveal a corpse inside that was charred beyond recognition, who appeared to have suffocated and/or burned to death during a fire that damaged most of the interior. I also noticed a number of strange tumors and growths on the body. I pressed a random button on the remains of what I believed to be a control panel, expecting nothing to happen, but the door closed automatically and I suddenly lost consciousness. When I came to, I exited the box, expecting to still be in the field in front of my house, but instead found myself a ways outside of a small snowy village that based on my best estimates, was somewhere in northern Asia around 2-3 thousand years ago. The villagers started coming after me with spears, so I quickly ran back to the box and pressed another button, hoping it would return me to from whence I came. This time, the people I found (who were thankfully much nicer and spoke a dialect of English that I could mostly understand) told me that it was the year 506 of the PGRB-Δ4 calendar (the calendar that the United Territories was using at the time). I repeated this maybe a dozen more times trying to get home until I landed in 2023, which as far as I could tell, was the closest I had gotten back to my original time so far. It was at this point that I decided to stay and seek medical attention, as I was rather concerned about some nasty new growths on my arms and legs similar to that which I had seen on the corpse.

FAQ: Where is the time machine now?

A: No idea. It disappeared a few days after I landed in 2023. My best guess is that some poor sap found it and ended up sometime else.

(I never ask for likes/reblogs but I literally spent fucking WEEKS on this one so if you liked it pls show me some love <3)

471 notes · View notes

mariacallous · 2 years ago

Text

A strange thing happened in the eurozone economy at the end of last year. Despite widespread forecasts that the common currency area would plunge into recession and register negative growth in the last quarter of 2022, it managed to eke out a small gain of 0.1 percent. What is remarkable is not that Europe beat expectations, but that it was one small country—Ireland—whose surging economy single-handedly prevented the eurozone from slipping into the red.

Almost unbelievably, little Ireland, with a population of only 5 million, now has the economic scale to shift the growth statistics of the entire eurozone and its 343 million inhabitants. In 2022, Irish GDP growth of 12.2 percent compared to 3.5 percent in the eurozone as a whole. In absolute numbers, only Germany, France, and Italy contributed more than Ireland to eurozone GDP growth in 2021 and 2022. Ireland’s economic boom has enabled the country’s government to post a budget surplus of 1.6 percent of GDP, even as eurozone countries struggled with an average deficit of more than 3 percent.

Honestly, who wouldn’t want this luck of the Irish?

Look closely, however, and Ireland’s so-called economic miracle looks more than a little odd. The country’s growth is simultaneously both real and artificial. Much of it is driven by a handful of U.S. multinationals, which continue to route global sales and profits through their Irish operations to take advantage of Dublin’s lower business taxes. Although difficult and complex to calculate, Apple’s shifting of intellectual property assets to Ireland is estimated to have contributed half of Ireland’s miraculous 26 percent GDP growth in 2016. That bizarre fact inspired New York Times columnist Paul Krugman to ridicule Ireland’s “leprechaun economics”—and the Irish statistics office to move away from using GDP as a measure of economic growth.

Yet the surge of U.S. investment in Ireland is also real. In particular, Ireland’s role as a pharmaceuticals manufacturing hub dramatically increased during the COVID-19 pandemic. Nine out of the world’s top 10 drug companies have significant production facilities in Ireland. The U.S. State Department thinks the corporate build-out in Ireland will continue, given Ireland’s status as the only remaining English-speaking European Union country following Britain’s departure. That makes it easy for international companies to operate and enjoy barrier-free access to the EU’s single market.

It’s hard to exaggerate Ireland’s dependence on U.S. tech and pharma companies for investment and taxes. Corporate tax receipts are now the second-largest source of tax revenue (after income tax) for the Irish state: 27 percent of all tax income in 2022. The average was just 9 percent in the 38 member countries of the Organisation for Economic Co-operation and Development (OECD) in 2020, the last year for which data is available. This, in turn, is fueling an unprecedented torrent of tax income for the Irish government. Corporate tax revenues were up nearly 50 percent in 2022 alone.

Just 10 multinationals—all of them U.S.-based tech and pharmaceutical companies—now pay nearly 60 percent of Ireland’s corporate tax. Directly and indirectly, U.S. multinationals employ more than 375,000 people in Ireland, approximately 15 percent of the country’s labor force. Driven by investment from the United States, foreign multinationals now account for 53 percent of all payroll taxes paid by corporate employers.

Driven by the windfall in corporate tax receipts, the Irish government’s budget surplus is expected to swell further, to 10 billion euros in 2023 and 16 billion euros in 2024. Relative to the size of the economy, this would be equivalent to a U.S. budget surplus of more than 1 trillion dollars in 2024.

The problem for Ireland is that this singular dependence exposes the country to growing risks. Take the tech sector: As multinationals like Google, Microsoft, Meta, and Amazon see their profits shrink and slash jobs worldwide, it will not only hurt the Irish economy, but deprive Dublin of tax income as well.

What’s more, the threat to Ireland’s stability from its overdependence on U.S. companies is about to be multiplied. In 2021, nearly 140 tax jurisdictions, including Ireland, agreed to a major reform of how multinationals companies will be taxed in the future. Pillar 2 of these reforms—a minimum corporate tax rate of 15 percent for large companies—is already coming into effect. In 2024, Ireland’s corporate tax rate is due to increase to 15 percent from its current level of 12.5 percent, reducing its attractiveness as a tax haven compared to other countries. The United States also approved the minimum tax plan in August 2022, despite significant private sector and political opposition.

However, it is Pillar 1 of the OECD’s reforms that will dramatically erode Ireland’s future income from corporate taxes. This reform will reallocate a share of company profits to where sales (or users) are actually located. Previously, tax liability was calculated on where the company or its subsidiary was legally based, no matter how many profits it rerouted from other parts of the world for tax-avoiding purposes. For Ireland, the consequences are obvious: U.S. multinationals operating in the EU will be forced to divide some of their sales by member state, thus significantly reducing the amount of sales and profits that can be “booked” through Ireland. This reform is due to come into force in 2024. The end of Ireland’s windfall is therefore only a matter of time.

The Irish Department of Finance estimated in January that around half of Ireland’s corporate tax receipts—$10 billion—are “transitionary” and will be lost as the new tax rules are implemented. That translates to more than 10 percent of total government spending in 2022—more than the entire Irish education budget. This is putting the Irish government on the precipice of another financial disaster, little more than a decade after it had to be bailed out of impending bankruptcy by the European Commission, European Central Bank, and the International Monetary Fund. That disaster left Ireland with one of the highest per capita public debt levels in the world.

Regardless of the impending financial train wreck, however, Dublin is unlikely to wake up from its American dream anytime soon. Diversifying its economy and revenue sources away from U.S. multinationals would require Ireland to shift its economic and geopolitical orientation, downgrade (in Dublin’s eyes) its deep relationship with the United States, and seek greater integration into the EU economy and its myriad rules.

That’s because Ireland’s dependence on U.S. multinationals is just another expression of the country’s affinity with the United States—the “shared heritage” referenced by U.S. presidents from John F. Kennedy to Ronald Reagan to Joe Biden. These ties to the United States long precede Dublin’s embrace of European integration and make it unlikely that Ireland will ever have the same intensity of economic, cultural, and other ties to France, Germany, or the rest of the EU.

The approaching economic and fiscal train wreck resulting from the new tax rules requires a fundamental change of mindset from Irish policymakers. Squaring the circle—holding on to its deep U.S. ties while integrating more closely with the EU to diversify its economy—means Dublin must give a little (and lose a little) to both sides. Yet Ireland’s ability to navigate this conundrum is doubtful. Even though the coming changes have been plain for all to see, Dublin’s current Trade and Investment Strategy does not contain any concrete policies to mitigate the overdependence on U.S. investment flows. Although the document acknowledges that EU market opportunities are underutilized, it again recognizes the importance “markets such as the UK and the US, which offer familiarity with language and culture.”

If there is no short-term solution to Ireland’s financial vulnerabilities, a few longer-term needs stand out. Dublin should ensure that its current budget surplus is invested wisely to help diversify its drivers of growth. One such driver would be significant increases in public investment in housing and public transport infrastructure to bring the country closer to Western European standards. Ireland’s tax base should be widened to allow for a wider distribution of income sources. For example, In 2021, Ireland gained just 5 percent of its tax receipts from property taxes, compared to more than 11 percent in both Britain and the United States.

Most importantly, Ireland must deepen its trading relationships outside the English-speaking world. Notwithstanding the country’s 50-year membership of the EU, a dearth of foreign language teaching has created a monolingual business culture, which priorities existing links with the United States over the development of new markets, both within and outside the EU. This needs to change if Ireland is to build a sustainable economic model.

Biden—whose family, like so many in the United States, has Irish roots—said in 2021 that “everything between Ireland and the United States runs deep.” This is Ireland’s economic reality today. As the corporate tax boom ebbs, Ireland should ensure that its American dream doesn’t become a recurring economic and financial nightmare.

2 notes · View notes

insideoutvietnam · 15 days ago

Text

Global Medical Devices Manufacturer Selects Kneat to Digitize Validation

LIMERICK, Ireland, Oct. 31, 2024 (GLOBE NEWSWIRE) — kneat.com, inc. (TSX: KSI) (OTC: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a global and diverse medical devices manufacturer has signed a three-year Master Services Agreement with Kneat to digitize its validation processes. The Company provides solutions to the pharma, biotech and…

View On WordPress

#GlobeNewswire

0 notes

harshnews · 26 days ago

Text

Cataplexy Treatment Market Size, Share, Trends, Opportunities, Key Drivers and Growth Prospectus

"Global Cataplexy Treatment Market - Industry Trends and Forecast to 2028

Global Cataplexy Treatment Market, By Treatment (Sodium Oxybate, Tricyclic Antidepressant, Amphetamines, Selective Serotonin Uptake Reinhibitors (SSRIs), Modafinil), Dosage (Tablet, Solution, Capsule, Others), Route of Administration (Oral, Other), Diagnosis (Physical Evaluation, Written Evaluation, Polysomnogram, Multiple Sleep Latency Test (MSLT)), Symptoms (Drooping Eyelids, Jaw Tremor, Facial Twitching, Flickering, Speech Difficulty, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Access Full 350 Pages PDF Report @

**Segments**

- By Treatment Type: The cataplexy treatment market can be segmented based on treatment type into medication and therapy. Medications can further be categorized into selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and sodium oxybate, among others. Therapy options may include cognitive-behavioral therapy (CBT) and lifestyle changes. - By Distribution Channel: Distribution channels in the cataplexy treatment market include hospitals, retail pharmacies, and online pharmacies. Each of these channels plays a crucial role in ensuring that cataplexy patients have access to the necessary medications and therapies.

**Market Players**

- Jazz Pharmaceuticals: As a key player in the cataplexy treatment market, Jazz Pharmaceuticals offers Xyrem, a medication containing sodium oxybate that is approved for the treatment of cataplexy in patients with narcolepsy. - Bioprojet Pharma: Bioprojet Pharma is known for its involvement in the research and development of medications for narcolepsy and cataplexy. Their flagship product, pitolisant (Wakix), has shown efficacy in the treatment of cataplexy. - Teva Pharmaceuticals: Teva Pharmaceuticals is a prominent player in the pharmaceutical industry and offers medications for various central nervous system disorders, including cataplexy in patients with narcolepsy. - Mylan N.V.: Mylan N.V. is a global pharmaceutical company that provides affordable access to medications for cataplexy treatment, ensuring a broader reach for patients in need of such therapies.

The global cataplexy treatment market is witnessing growth due to an increasing prevalence of narcolepsy and an expansion of treatment options available to patients. Factors such as the rising awareness regarding cataplexy, advancements in medical technology, and the development of novel therapies are driving market growth. Market players are focusing on research and development activities to introduce innovative treatment options while also expanding their distribution networks to enhance patient access to medications.The global cataplexy treatment market is experiencing significant growth driven by several key factors. With the increasing prevalence of narcolepsy, which often coexists with cataplexy, there is a growing need for effective treatment options to manage the symptoms of these debilitating conditions. The expansion of treatment options, including medications and therapies, has provided patients with more choices to address their cataplexy symptoms. This increase in treatment options has been fueled by advancements in medical technology, which have enabled the development of novel therapies that show promise in effectively managing cataplexy.

One of the primary drivers of market growth is the rising awareness surrounding cataplexy and its impact on individuals' quality of life. As awareness of cataplexy increases among healthcare professionals and the general public, more emphasis is being placed on the importance of timely diagnosis and management of the condition. This heightened awareness has led to earlier detection of cataplexy in patients with narcolepsy, ensuring that appropriate treatments are administered promptly to improve patients' overall well-being.

Market players in the cataplexy treatment market are actively engaged in research and development activities to introduce innovative treatment options that address the specific needs of patients with cataplexy. These efforts have resulted in the introduction of new medications and therapies that offer improved efficacy and safety profiles compared to traditional treatment options. Additionally, market players are expanding their distribution networks through partnerships with hospitals, retail pharmacies, and online pharmacies to enhance patient access to these innovative treatments.

The competitive landscape of the cataplexy treatment market is characterized by key players such as Jazz Pharmaceuticals, Bioprojet Pharma, Teva Pharmaceuticals, and Mylan N.V. These companies have established themselves as leaders in the market through their focus on developing and commercializing medications for cataplexy treatment. Jazz Pharmaceuticals, for example, offers Xyrem, a medication containing sodium oxybate that has proven effective in managing cataplexy symptoms in patients with narcolepsy. Similarly, Biopro**Global Cataplexy Treatment Market, By Treatment:** - Sodium Oxybate - Tricyclic Antidepressant - Amphetamines - Selective Serotonin Uptake Reinhibitors (SSRIs) - Modafinil

**Dosage:** - Tablet - Solution - Capsule - Others

**Route of Administration:** - Oral - Other

**Diagnosis:** - Physical Evaluation - Written Evaluation - Polysomnogram - Multiple Sleep Latency Test (MSLT)

**Symptoms:** - Drooping Eyelids - Jaw Tremor - Facial Twitching - Flickering - Speech Difficulty - Others

**End-Users:** - Clinic - Hospital - Others

**Distribution Channel:** - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy

**Country:** - U.S. - Canada - Mexico - Brazil - Argentina - Peru - Rest of South America - Germany - France - U.K. - Netherlands - Switzerland - Belgium - Russia - Italy - Spain - Turkey - Hungary - Lithuania - Austria - Ireland - Norway - Poland - Rest of Europe - China - Japan - India - South Korea - Singapore - Malaysia - Australia - Thailand - Indonesia - Philippines - Vietnam - Rest

Key points covered in the report: -

The pivotal aspect considered in the global Cataplexy Treatment Market report consists of the major competitors functioning in the global market.

The report includes profiles of companies with prominent positions in the global market.

The sales, corporate strategies and technical capabilities of key manufacturers are also mentioned in the report.

The driving factors for the growth of the global Cataplexy Treatment Market are thoroughly explained along with in-depth descriptions of the industry end users.

The report also elucidates important application segments of the global market to readers/users.

This report performs a SWOT analysis of the market. In the final section, the report recalls the sentiments and perspectives of industry-prepared and trained experts.

The experts also evaluate the export/import policies that might propel the growth of the Global Cataplexy Treatment Market.

The Global Cataplexy Treatment Market report provides valuable information for policymakers, investors, stakeholders, service providers, producers, suppliers, and organizations operating in the industry and looking to purchase this research document.

What to Expect from the Report, a 7-Pointer Guide

The Cataplexy Treatment Market report dives into the holistic Strategy and Innovation for this market ecosystem

The Cataplexy Treatment Market report keenly isolates and upholds notable prominent market drivers and barriers

The Cataplexy Treatment Market report sets clarity in identifying technological standardization as well as the regulatory

framework, besides significantly assessing various implementation models besides evaluation of numerous use cases

The Cataplexy Treatment Market report is also a rich repository of crucial information across the industry, highlighting details on novel investments as well as stakeholders and relevant contributors and market participants.

A through market analytical survey and forecast references through the forecast tenure, encapsulating details on historical developments, concurrent events as well as future growth probability

Browse Trending Reports:

Forage Harvester Market Calcify Uremic Arteriolopathy Drug Market Alexipharmic Drugs Market Resectoscope Market Coal To Liquid Market Air Electrode Battery Market Power Sports Batteries Market Body Scrub Market Cataplexy Treatment Market Alveolar Capillary Dysplasia Treatment Market Quantum Computing Market Control Valves Market Hemodialysis Peritoneal Dialysis Market Breathable Films Market Utility Locator Market Food Humectants Market Electronic Safety System Market Reporter Gene Assay Market Security Assertion Markup Language Saml Authentication Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

#Cataplexy Treatment Market

0 notes

amrutatbrc1 · 2 months ago

Text

Blister Packaging Machinery Consumption Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033

The blister packaging machinery consumption global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Blister Packaging Machinery Consumption Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The blister packaging machinery consumption market size has grown strongly in recent years. It will grow from $23.52 billion in 2023 to $25.62 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to growth in pharmaceutical and healthcare industries, demand for tamper-evident and child-resistant packaging, stringent regulatory requirements for pharmaceutical packaging, increased in over-the-counter (otc) drug sales, expansion of consumer goods and electronics packaging.

The blister packaging machinery consumption market size is expected to see strong growth in the next few years. It will grow to $36.21 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rise in contract manufacturing and packaging services, market expansion in emerging economies and healthcare access improvement, demand for sustainable and eco-friendly packaging solutions, customization and flexibility in blister packaging equipment, increasing adoption of blister packaging in cosmetics and personal care. Major trends in the forecast period include integration of industry 4.0 technologies, modular and flexible packaging lines, smart packaging solutions, sustainable and recyclable materials, high-speed and high-throughput machinery, advanced feeding and handling systems.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/blister-packaging-machinery-consumption-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - The rising demand for the pharma industry is expected to propel the blister packaging market. The high economic growth, combined with increasing health insurance penetration, has increased spending on healthcare and medicine. Furthermore, People's reliance on medication grows as they live longer lives with better access to treatment. The ability of the market to produce high-quality, low-cost medicines represents a massive business opportunity for the domestic industry. The insurance industry also influences medical spending. This increased demand in medicine has pushed the use of blister packaging machinery market to protect products against external factors, such as humidity and contamination, for extended periods. For Instance, according to Enterprise Ireland's published report on the UK pharmaceutical sector, the value of the UK pharmaceutical sector is expected to rise by 19.3% to £25 billion ($30.26) between 2018 and 2023, representing a 3.6% annual increase. Therefore, the rising demand for the pharma industry will drive the growth of the blister packaging machinery consumption market.

The blister packaging machinery consumption market covered in this report is segmented –

1) By Technology: Thermoforming, Cold Forming 2) By Type: Carded, Clamshell 3) By Material: Plastic, Paper, Aluminium 4) By Application: Pharmaceutical Industry, Food Industry, Cosmetics And Personal Care, Consumer Electronics

Get an inside scoop of the blister packaging machinery consumption market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=7752&type=smp

Regional Insights - Asia-Pacific was the largest region in the blister packaging machinery market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the blister packaging machinery consumption market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major companies operating in the blister packaging machinery consumption market include WestRock Company, Sonoco Products Company, Tekni-Plex Inc., Display Pack Inc., Pharma Packaging Solutions, Winpak Ltd., SteriPack Group, DuPont de Nemours Inc., Perlen Packaging, Uhlmann Group, Industria Macchine Automatiche S.p.A., Robert Bosch GmbH, Marchesini Group S.p.A., Romaco Pharmatechnik GmbH, Sepha Ltd., ILLIG Maschinenbau GmbH & Co. KG, Algus Packaging Inc., Mediseal GmbH, Fabrima Maquinas Automaticas Ltda., Costruzioni Apparecchiature Macchine S.r.l., Starview Packaging Machinery Inc., Zed Industries Inc., Visual Packaging Group, Rohrer Corporation, Ecobliss Holding BV, Prent Corporation, Tekpak Solutions

Table of Contents 1. Executive Summary 2. Blister Packaging Machinery Consumption Market Report Structure 3. Blister Packaging Machinery Consumption Market Trends And Strategies 4. Blister Packaging Machinery Consumption Market – Macro Economic Scenario 5. Blister Packaging Machinery Consumption Market Size And Growth ….. 27. Blister Packaging Machinery Consumption Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

healthcareanna · 3 months ago

Text

Contrast Media Market Size, Trends, Growth Forecast 2032

Contrast Media Market Overview

Market Research Future (MRFR) predicts the Global Contrast Media Market size was valued at USD 6.36 Billion in 2023. The Global Contrast Media industry is projected to grow from USD 6.74 Billion in 2024 to USD 18.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.76% during the forecast period (2024 - 2032). The radiographic contrast agents market is characterized by a dynamic interplay of technological advancements, evolving regulatory landscapes, and growing demand for diagnostic imaging procedures. Radiographic contrast agents, often referred to as contrast media, play a pivotal role in enhancing the visibility of anatomical structures during medical imaging procedures such as X-rays, computed tomography (CT), and fluoroscopy. These agents are formulated to selectively absorb or scatter X-rays, thereby accentuating the contrast between different tissues or organs within the body. As medical imaging technologies continue to advance, there is a corresponding increase in the diversity and efficacy of radiographic contrast agents, driving market growth.

Contrast Media Market Key players

Prominent contrast media companies are

AMAG Pharmaceuticals (US)

Bracco Diagnostic Inc. (Italy)

Lantheus Medical Imaging (U.S.)

Covidien (Ireland)

Mallinckrodt Pharmaceuticals (UK)

Targeson (US)

nanoPET Pharma GmbH (Germany)

NanoScan Imaging (US)

Medrad Inc. (US)

Guerbet Group (France)

Subhra Pharma Private Limited (India)

GE Healthcare (US)

CMC Contrast AB (Sweden)

Daiichi (Japan)

Bayer Healthcare Pharmaceuticals (Germany)

Latest Innovation on Contrast Media Market

Advanced MRI Contrast Agents

Recent innovations in MRI contrast agents include the development of new gadolinium-based compounds with improved safety profiles and enhanced imaging capabilities. These advanced agents offer higher resolution images and better tissue differentiation, which can lead to more accurate diagnostics and reduced need for follow-up imaging.

Hybrid Contrast Agents for Multimodal Imaging

New hybrid contrast agents are being developed to work across multiple imaging modalities, such as MRI, CT, and ultrasound. These agents provide versatility and improved diagnostic accuracy by allowing for comprehensive imaging assessments with a single contrast medium, reducing patient exposure to multiple agents and optimizing workflow efficiency.

Iodinated contrast media are widely used in radiographic imaging studies such as computed tomography (CT) scans and angiography. These contrast agents contain iodine, which has a high atomic number and excellent X-ray attenuation properties, making it ideal for enhancing contrast in X-ray images. Iodinated contrast media are administered orally, intravenously, or rectally, depending on the imaging modality and the area of the body being examined.

Contrast Media Market Segmentation

The segmental study of the Global Contrast Media Market gives a compendious market overview that highlights key points of the market that benefits our clients to identify growth opportunities of the market. The contrast media market study is segmented into type, procedure, application, and route of application.

Based on the type, the market is segmented into intravenous contrast materials, iodine-based contrast media agents, and others.

Based on the application, the market is segmented into nephrological disorders, oncology, cardiovascular disorders, and others.

Based on the route of administration, the market is segmented into injectable, rectal, and oral.

Gadolinium-based contrast agents are commonly used in magnetic resonance imaging (MRI) studies to improve image contrast and delineate structures with greater clarity. These contrast agents contain gadolinium, a paramagnetic metal that alters the magnetic properties of tissues and enhances signal intensity on MRI images.

Contrast Media Market Regional Insights

MRFR’s regional analysis of the Contrast Media Market gives a holistic approach towards the demographic progress of the market in the forecast years. Based on the region, the contrast media market is segmented into Asia Pacific, North America, Europe, and the Rest-of-the-World (RoW).

North America is expected to dominate the market, holding a significant market share owing to its strong technological infrastructure. Increase in medical tourism, rise in the number of cancer patients and patients suffering from chronic disorders, and market players likely to deliver cost-competitive contrast media products are factors which are predicted to fuel the regional market growth.

Robust economic improvement, existence of influential market players, and technological advancements in the European region can augment the regional market proliferation.

The contrast media market in the Asia Pacific region, led by the rapidly proliferating healthcare sector and developing economy, has emerged as a promising market, globally. Increasing markets in countries, such as Japan, China, and India, are pushing up the growth in the regional market. Moreover, the APAC Contrast Media Market is driven by the rising population and the spreading awareness towards the functionalities of contrast media.

The rapidly growing healthcare industry and emerging economies like India, Japan, and China in the Asia Pacific region, a huge population, and increase in awareness towards benefits of contrast media are market dynamics expected to drive the regional market growth.

Browse Related Reports-

Blood Glucose Monitoring market

Syringe and Needle market

Dental Implants market

Stem Cell Manufacturing market

Automatic Pill Dispenser market

#Contrast Media Market Size

0 notes

hamzaaslam · 3 months ago

Text

Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets

SINGAPORE – Media OutReach Newswire – 28 August 2024 – Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T…

0 notes

chemxpert · 4 months ago

Text

The Role of Activated Pharmaceutical Ingredients in Modern Medicine

An Active Pharmaceutical Ingredient (API) is the biologically active component in a pharmaceutical product. It is the substance in a drug that produces the intended effects, whether to treat a specific condition, alleviate symptoms, or prevent diseases. APIs can be found in various forms, including powders, crystals, and solutions, and are the result of a complex chemical synthesis or extraction process.

#pharmaceutical manufacturing companies in India #pharmaceutical industries in USA #global pharmaceutical industry #pharma companies in Ireland #medicine distributorship

1 note · View note

thoughtlessarse · 4 months ago

Text

Investigate Europe finds 15 of the world’s biggest drugmakers operate more than 1,300 subsidiaries in tax havens, as they amassed over €580 billion in global profits over the past five years. Meanwhile, patients face life-threatening delays for medicines due to high drug prices. When doctors removed Miriam Staunton's tumour from her armpit six years ago, they told the 51-year-old Irish woman that she had a 70 per cent chance of relapse. Yet, in the months following the operation, she was only offered local radiation and regular check-ups, but no drug treatment. "I remember when I met the oncologist and he said that he wasn't in a position to offer me anything systemic at that point," Staunton recalls. "I didn't really understand exactly what he meant by it at that time." What Staunton did not realise is that she would have to wait for her melanoma to return one year later before she could be entitled to effective but expensive medicines. After the cancer had progressed to stage four in February 2019, she started a course of Opdivo combined with Yervoy, breakthrough drugs known as immunotherapy, which were then restricted to the most severe forms of cancer in Ireland due to their high costs. In other parts of Europe, Staunton could have taken Opdivo alone shortly after her surgery. In July 2018, the European Medicines Agency (EMA) opened the therapy to stage three melanoma patients. France immediately reimbursed it, but Ireland did not. "It's one thing when there is no cure, but when the treatment exists and people can't access it, that's fundamentally wrong," says Staunton, who is now cancer-free. The reason for this delay is that Ireland and the American drugmaker, Bristol-Myers Squibb (BMS), could not agree on Opdivo's price. When the EMA approves new medicines for use in the EU, each member state has to strike reimbursement deals with producers individually. Negotiations can be lengthy, as companies often prioritise rich markets and governments seek confidential discounts. Meanwhile, the pharmaceutical industry - like many other sectors - hoards eye-watering gains in tax havens. Investigate Europe can reveal that the 15 largest European and US drugmakers, including BMS, publicly disclose over 1,300 subsidiaries in tax havens and low-tax territories.

#eu #big pharma #drug costs #tax havens #capitalism

0 notes

harshnews · 1 month ago

Text

Necrotizing Enterocolitis Treatment Market Size, Share, Trends, Growth Opportunities and Competitive Outlook

"Necrotizing Enterocolitis Treatment Market - Industry Trends and Forecast to 2028

Global Necrotizing Enterocolitis Treatment Market, By Type (Suspected, Definite, Advanced), Treatment (Oral Medication, Botulinum Toxin and Surgery), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Access Full 350-page PDF Report @

**Segments**

- On the basis of treatment type, the necrotizing enterocolitis treatment market can be segmented into surgical treatment, medication, and others. Surgical treatment involves removing the necrotic portions of the intestines and may be required in severe cases of necrotizing enterocolitis. Medication includes antibiotics to fight infections and other drugs to help manage symptoms and facilitate healing. Other treatment options may involve nutritional support and close monitoring of the patient's condition.

- By end-user, the market can be categorized into hospitals, ambulatory surgical centers, and specialty clinics. Hospitals are the key contributors to the market revenue due to the availability of advanced infrastructure and skilled healthcare professionals. Ambulatory surgical centers are gaining traction as they offer cost-effective treatment options for necrotizing enterocolitis. Specialty clinics focus on providing specialized care and treatment for patients with complex medical conditions.

- Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market due to the high prevalence of necrotizing enterocolitis cases, well-established healthcare infrastructure, and increasing research and development activities. Europe follows closely behind, driven by advancements in medical technology and favorable reimbursement policies. Asia Pacific is expected to witness significant growth with improving healthcare facilities and rising awareness about the condition.

**Market Players**

- Some of the key players in the necrotizing enterocolitis treatment market include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Limited. These companies are actively involved in research and development activities to introduce innovative treatment options for necrotizing enterocolitis. Partnerships, collaborations, and acquisitions are common strategies adopted by these market players to strengthen their market presence.

For more information, you can visit https://The global necrotizing enterocolitis treatment market is witnessing steady growth driven by several factors such as increasing prevalence of the condition, advancements in healthcare infrastructure, and ongoing research and development efforts by key market players. The treatment landscape for necrotizing enterocolitis is diversified, with options including surgical interventions, medications, and supportive therapies. Surgical treatment involves the removal of necrotic portions of the intestines in severe cases, while medications such as antibiotics and other drugs play a crucial role in managing infections and symptoms. Other treatment modalities focus on nutritional support and close monitoring to ensure optimal patient outcomes.

In terms of end-users, hospitals remain the primary revenue generators in the necrotizing enterocolitis treatment market due to their advanced infrastructure and skilled healthcare professionals. Ambulatory surgical centers are gaining popularity for offering cost-effective treatment options, while specialty clinics cater to patients with complex medical conditions requiring specialized care. Geographically, North America leads the market due to a high prevalence of necrotizing enterocolitis cases, well-established healthcare systems, and increasing R&D activities. Europe follows closely behind with advancements in medical technology and favorable reimbursement policies, while the Asia Pacific region is poised for significant growth driven by improving healthcare facilities and growing awareness about the condition.

Key players in the necrotizing enterocolitis treatment market, such as AbbVie Inc., GlaxoSmithKline plc, Pfizer Inc., and Sanofi, are actively engaged in research and development initiatives to introduce innovative treatment solutions. These companies leverage partnerships, collaborations, and acquisitions to strengthen their market foothold and expand their product portfolios. With a focus on enhancing treatment outcomes and addressing unmet medical needs, market players are investing in novel therapies and precision medicine approaches to improve patient care and drive market growth.

Looking ahead, the necrotizing enterocolitis treatment market is poised for further expansion, fueled by increasing disease awareness, growing healthcare expenditure, and advancements in medical technology. Research into personalized treatment strategies, biomarker development, and novel therapeutic**Segments**

- Global Necrotizing Enterocolitis Treatment Market, By Type (Suspected, Definite, Advanced), Treatment (Oral Medication, Botulinum Toxin and Surgery), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

The global necrotizing enterocolitis treatment market is witnessing significant growth due to a rise in the prevalence of the disease, advancements in healthcare infrastructure, and ongoing research and development efforts by key market players. The market can be segmented based on treatment type into surgical treatment, medication, and others. Surgical treatment involves the removal of necrotic portions of the intestines, while medication includes antibiotics and other drugs to manage symptoms. Other treatment options focus on providing nutritional support and closely monitoring the patient's condition.

By end-users, the market is categorized into hospitals, ambulatory surgical centers, and specialty clinics. Hospitals play a crucial role in generating market revenue due to advanced infrastructure and skilled healthcare professionals. Ambulatory surgical centers are gaining popularity for offering cost-effective treatment options for necrotizing enterocolitis. Specialty clinics cater to patients with complex medical conditions, providing specialized care and treatment.

Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America leads the market with a high prevalence of necrotizing enterocolitis cases,

Table of Content:

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Global Necrotizing Enterocolitis Treatment Market Landscape

Part 04: Global Necrotizing Enterocolitis Treatment Market Sizing

Part 05: Global Necrotizing Enterocolitis Treatment Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Objectives of the Report

To carefully analyze and forecast the size of the Necrotizing Enterocolitis Treatment market by value and volume.

To estimate the market shares of major segments of the Necrotizing Enterocolitis Treatment

To showcase the development of the Necrotizing Enterocolitis Treatment market in different parts of the world.

To analyze and study micro-markets in terms of their contributions to the Necrotizing Enterocolitis Treatment market, their prospects, and individual growth trends.

To offer precise and useful details about factors affecting the growth of the Necrotizing Enterocolitis Treatment

To provide a meticulous assessment of crucial business strategies used by leading companies operating in the Necrotizing Enterocolitis Treatment market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches.

Key questions answered

How feasible is Necrotizing Enterocolitis Treatment Market for long-term investment?

What are influencing factors driving the demand for Necrotizing Enterocolitis Treatment near future?

What is the impact analysis of various factors in the Global Necrotizing Enterocolitis Treatment market growth?

What are the recent trends in the regional market and how successful they are?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America

Browse Trending Reports:

About Data Bridge Market Research:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

#Necrotizing Enterocolitis Treatment Market

0 notes

aimarketresearch · 7 months ago

Text

Biosimilar Market Size, Share, Key Growth Drivers, Trends, Challenges and Competitive Landscape

Data Bridge Market research has recently issued comprehensive industry research on Global Biosimilar Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report.

Besides, Biosimilar market report studies market growth opportunities and restraining factors. The geographical division of this market analysis report offers data that gives an idea of the revenue of the companies and sales figures of the market growth. The market report also contains the drivers and restraints for the Biosimilar market that are obtained with the help of SWOT analysis, and also shows all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands with their systemic company profiles, that are driving the market.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the global biosimilar market which was USD 37,270.20 million in 2022, is expected to reach USD 343,520.90 million by 2030, and is expected to undergo a CAGR of 32.00% during the forecast period 2023-2030. “Oncology” dominates the product segment of the global biosimilar market owing to the owing to the increase in number of research studies, increasing research and development activities by key players focused on oncology and advancements in healthcare technologies. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Key Questions Answered with this Study

1) What makes Biosimilar Market feasible for long term investment?

2) Know value chain areas where players can create value?

3) Teritorry that may see steep rise in CAGR & Y-O-Y growth?

4) What geographic region would have better demand for product/services?

5) What opportunity emerging territory would offer to established and new entrants in Biosimilar Market?

6) Risk side analysis connected with service providers?

7) How influencing factors driving the demand of Biosimilarin next few years?

8) What is the impact analysis of various factors in the Global Biosimilar Market growth?

9) What strategies of big players help them acquire share in mature market?

10) How Technology and Customer-Centric Innovation is bringing big Change in Biosimilar Market?

Some of the major players operating in the global biosimilar market are:

Novartis AG (Switzerland)

Orion Pharma AB (Sweden)

Pfizer Inc. (U.S.)

Samsung Bioepis. (South Korea)

Coherus BioSciences, Inc. (U.S.)

Amgen Inc. (U.S.)

Eli Lilly and Company (U.S.)

Takeda Pharmaceutical Company Limited. (Japan)

Bristol-Myers Squibb Company (U.S.)

Merck KGaA (Germany)

Teva Pharmaceutical Industries Ltd. (U.S.)

Biocon. (India)

Bayer AG (Germany)

AbbVie Inc. (U.S.)

Allergan (Ireland)

Dr. Reddy’s Laboratories Ltd. (India)

Boehringer Ingelheim International GmbH. (Germany)

Biogen (U.S.)

Browse Trending Reports:

Prenatal Testing And New Born Screening Market

Rapid Oral Fluid Screening Device Market

North America Eclinical Solutions Market

Medical Tuning Fork Market

North America Cbct Dental Imaging Market

Myopia Treatment Market

Induced Pluripotent Stem Cells Market

Pneumococcal Vaccine Market

Dupuytrens Disease Market

Mitogen Activated Protein Kinase Mapk Inhibitors Therapeutics Market

Neonatal Seizures Drugs Market

Chikungunya Treatment Market

Sickle Cell Disease Treatment Market

About Data Bridge Market Research:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]

0 notes

hypeptide · 11 months ago

Text

2023 global peptide event overview delivery

Part1 Financing/BD Event

December 2023

Kintide Pharmaceuticals completed US$8 million in seed round financing to advance a highly integrated computational design-automated synthetic peptide drug discovery platform

Roche acquires Carmot Therapeutics for over US$3 billion, entering the GLP-1 competition

Fractyl Health said in a regulatory filing that it plans to conduct an IPO in 2024. The company is committed to developing innovative treatments for type 2 diabetes and obesity, and the funds raised will be used to advance the development of its pipeline, including a gene therapy that expresses a GLP-1 receptor agonist in the pancreas.

Amide Technologies announced that it has begun commercializing its novel peptide manufacturing platform and has completed $16.5Mn in financing, including a $7.5Mn Series A+ round led by Engine Ventures with participation from Forcefield Venture Fund. It previously raised a $3.55Mn Series A round led by Engine Ventures and a $5.45Mn Seed round led by Biological Engineering Ventures.

Alkermes plc announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland, to Novo Nordisk. Under the terms of the agreement, upon completion of the transaction, Alkermes will be entitled to a one-time cash payment of $92.5Mn for the facility and associated assets, subject to customary adjustments in accordance with the agreement.

November 2023

Zhifei Biotech plans to acquire 100% equity of Chongqing Chenan Biopharmaceutical Co., Ltd. in cash to enter the GLP-1 field

Chengdu Taihe Weiye Biotechnology Co., Ltd. completed nearly 300 million yuan in Series A+ financing to accelerate the company’s Fmoc amino acid production capacity construction

Peptide Biotech completed nearly 200 million yuan in Series B+ financing to promote the development of GLP-1 products

lmagine Pharma completed US$32.5 million in Series A financing to develop new peptide IMG-1 and other projects

September 2023

PeptiDream enters into a new multi-target collaboration and licensing agreement with Genentech, a Roche company, to discover and develop novel macrocyclic peptide-radioisotope (peptide-RI) conjugates

Elicio Therapeutics receives $2.6 million foundation grant to fund research into two therapeutic cancer peptide vaccines

Shenzhen Tuosheng Biotechnology Co., Ltd. announced the completion of tens of millions of RMB Pre-A round of financing

August 2023

PeptiGrowth Inc (PeptiGrowth) and Orizuru Therapeutics, Inc (OZTx) have signed a joint development agreement to create a new synthetic peptide to replace recombinant growth factors used in the production of regenerative medicine products

HBC lmmunology completed US$900,000 in seed round financing to advance the research and development of peptide drugs

June 2023

Sino Biopharmaceuticals and Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd. have reached a cooperation agreement to jointly develop the dual-target innovative weight loss drug GMA106. GMA106 is a dual-target drug mainly suitable for the treatment of obesity, non-alcoholic fatty liver disease and diabetes

May 2023

Carmot Therapeutics announces raising $150 million in super Series E funding to advance its development of treatments for obesity and diabetes

lronwood successfully acquires next-generation GLP-2 through acquisition of VectivBio for $1 billion

Annual Highlights of Blockbuster Products

December 2023

Eli Lilly announced that its injectable Zepbound (Tirzepatide) is now available in U.S. pharmacies

Lisata Therapeutics announced that it has completed enrollment in the Phase IIb ASCEND study of its novel drug LSTA1 for the treatment of metastatic pancreatic ductal adenocarcinoma (“mPDAC”), achieving a key milestone.

Italian company Nerviano Medical Sciences (NMS) and Spanish pharmaceutical company Italfarmaco (ITF) jointly announced that ITF will use NMS’s proprietary linker-payload technology to develop a new PDC product candidate.

Apellis presented post-hoc data for its bicyclic peptide drug EMPAVELI® (pegcetacoplan) at the ASH Annual Meeting that strengthen the efficacy of EMPAVELI (pegcetacoplan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) for up to three years. years of long-term efficacy and safety.

November 2023

Eli Lilly announced that its GIP/GLP-1 receptor dual agonist Zepbound (Tirzepatide) has been approved by the U.S. FDA to reduce weight and maintain weight stability in obese or overweight adult patients.

Novo Nordisk released its results for Q3 and the first three quarters of 2023. Sales of semaglutide in the first three quarters have exceeded US$14.2 billion.

Eli Lilly and Company released its financial report for the third quarter of 2023. Sales of Tirzepatide in the first three quarters have reached US$2.957 billion.

October 2023

Novo Nordisk announced that the Phase III clinical study FLOW of semaglutide in patients with type 2 diabetes and chronic kidney disease with renal insufficiency was terminated early due to excellent efficacy.

August 2023

Eli Lilly’s Tirzepatide Injection Submits Registration Application in China for Long-term Weight Management Indication in Adults

July 2023

Eli Lilly announced the results of two phase 3 clinical trials on tilpotide. The results showed that the average weight loss effect was as high as 26.6%, making it the most powerful weight loss drug in history.

Peptide drugs approved for marketing

December 2023

Tonghua Dongbao Pharmaceutical’s marketing application for biosimilar GLP-1 analog liraglutide injection filed under registration classification 3.3 has been approved

Ascendis Pharma announced that the FDA has accepted the company’s resubmitted New Drug Application for palopegteriparatide (TransCon PTH) for the treatment of adult patients with hypoparathyroidism.

The National Medical Insurance Administration officially announced the adjustment list of the 2023 version of the National Medical Insurance Drug Catalog. The new round of medical insurance catalog includes four popular GLP-1 products. These include Renhui Biotech’s benaglutide injection, Lilly’s dulaglutide injection, Hanson Pharmaceuticals’ polyethylene glycol loxenatide injection, Novo Nordisk’s semaglutide injection, etc.

September 2023

BioLineRx announces FDA approval of Aphexda (motixafortide) combined with filgrastim (granulocyte colony-stimulating factor G-CSF) to mobilize hematopoietic stem cells into the peripheral blood as a stem cell mobilization (SCM) to promote autologous transplantation in patients with multiple myeloma at the time of transplantation

The marketing application for new indications of Lilly’s dulaglutide injection (trade name: Duida) was approved

July 2023

Renhui Biotech’s benaglutide has been approved for marketing as a new indication for weight loss. This is the first original new weight loss drug in China, and the injection frequency is three times a day.

East China Medicine’s Liraglutide Injection is approved for marketing for obesity or overweight indications

June 2023

Hansoh Pharmaceutical’s Class 1 new drug “Pemoxatide Injection” (trade name: Saint Relais) was approved for marketing. This medicine is suitable for adult non-dialysis patients who are not receiving erythropoiesis stimulating agents (ESA), and adult dialysis patients who are receiving short-acting erythropoietin (EPO).

May 2023

Blue Earth Diagnostics’ radiohybrid prostate-specific membrane antigen (PSMA)-targeted PET imaging agent Posluma (flotufolastat F 18) injection (formerly known as 18F-rhPSMA-7.3) was approved by the FDA for marketing

March 2023

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years and Older

Cidara Therapeutics’ New Drug Application (NDA) for Rezafungin for the treatment of candidemia and invasive candidiasis was approved by the FDA

January 2023

Radius Health’s TYMLOS (abapatide) received U.S. FDA approval for new indication (osteoporosis)

Website: https://www.ks-vpeptide.com/aboutus.html

#peptides #biology

0 notes

themarketinsights · 1 year ago

Text

Zolpidem Tartrate Market is Booming Worldwide with Strong Growth Prospects

Latest released the research study on Global Zolpidem Tartrate Market, offers a detailed overview of the factors influencing the global business scope. Zolpidem Tartrate Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Zolpidem Tartrate The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Sanofi (France), Bachem (Switzerland), Taj Pharmaceuticals Limited (India), Sun Pharmaceutical Industries Ltd. (India), FARMAK (Ukraine), Gador (Argentina) , Hikma Pharmaceuticals (United Kingdom), Northstar Rx (United States), Teva Pharmaceuticals (Israel), Torrent Pharma (India), Apotex (Canada), Endo International plc (Ireland),

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/118224-global-zolpidem-tartrate-market

Zolpidem Tartrate Market Definition:

Zolpidem tartrate market has high growth prospects owing to the increasing prevalence of sleeping disorders and the growing geriatric population. Moreover, growth in the clinical research sector and growing healthcare infrastructure in the developing economies expected to drive the market demand during the forecasted period.

Market Trend:

Growing Clinical Research in the Healthcare Industry

Market Drivers:

Rising Prevalence of Sleeping Disorder

Growing Geriatric Population

Market Opportunities:

Growing Healthcare Infratstrure in the Developing Economies

The Global Zolpidem Tartrate Market segments and Market Data Break Down are illuminated below:

by Type (Zolpidem Tartrate Tablet, Zolpidem Tartrate Injection), Application (Hospitals, Clinics, Others)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/118224-global-zolpidem-tartrate-market

Strategic Points Covered in Table of Content of Global Zolpidem Tartrate Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Zolpidem Tartrate market

Chapter 2: Exclusive Summary – the basic information of the Zolpidem Tartrate Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Zolpidem Tartrate

Chapter 4: Presenting the Zolpidem Tartrate Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Zolpidem Tartrate market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2021-2026).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Zolpidem Tartrate Market is a valuable source of guidance for individuals and companies in decision framework.

Data Sources & Methodology The primary sources involves the industry experts from the Global Zolpidem Tartrate Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/118224-global-zolpidem-tartrate-market

What benefits does AMA research study is going to provide?

Latest industry influencing trends and development scenario

Open up New Markets

To Seize powerful market opportunities

Key decision in planning and to further expand market share

Identify Key Business Segments, Market proposition & Gap Analysis

Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837

0 notes

rupalic · 1 year ago

Text

Microencapsulation Market: Key Factors behind Market’s Rapid Growth

The report "Microencapsulation Market by Technology (Spray, Emulsion, Dripping), Core Material (Pharma & Healthcare Drugs, PCM, Food Additives, Fragrances), Application (Pharma, Household, Agrochemicals, Textiles), Shell Material, and Region - Global Forecast To 2025", The global microencapsulation market was valued at USD 8.5 billion in 2020 and is projected to reach USD 15.5 billion by 2025 at a CAGR of 12.9% from 2020 to 2025. The market is driven by factors such as the increasing demand for fortified food products with health benefits, the increasing demand for agrochemicals due to its controlled release property, growth in construction and construction materials, as well as the widespread application in household & personal care.

North America is estimated to dominate the microencapsulation market in 2020

North America accounted for the largest market share of the microencapsulation market in 2019. The market for microencapsulation in the North American region is driven by the growing demand and awareness for value-added products in various areas such as nutrition, food, healthcare, and personal care. Due to this awareness and increased demand, companies are focusing on manufacturing functional products, with novel technologies such as microencapsulation.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=83597438

This report includes a study on the marketing and development strategies, along with a study on the service portfolios of the leading companies. It includes the profiles of leading companies such as BASF (Germany), Royal FrieslandCampina (Netherlands), Syngenta Crop Protection (Switzerland), Koninklijke DSM (Netherlands), Givaudan (Switzerland), Firmenich (Switzerland), Symrise (Germany), International Flavors & Fragrances (US), Sensient Technologies (US), Lycored Corp. (UK), Balchem Corporation (US), Encapsys (US), Arcade Beauty (US), and Koehler Innovative Solutions (Germany), Ingredion Incorporation (US), Kerry (Ireland), Cargill (US), Firmenich Incorporation (Switzerland), Dupont (US), Aveka Group (US), Advanced Bionutrition Corp (US), Tastetech Encapsulation Solutions (UK), Sphera Encapsulation (Italy), Clextral (France), Vitasquare (Netherlands), and Microtek (US).

The pharmaceuticals and healthcare drugs segment, by application, is estimated to account for the largest share in 2020

Based on application, the microencapsulation market is segmented into pharmaceutical & healthcare products, household & personal care products, food & beverages, agrochemicals, textiles, construction materials, and others. The pharmaceuticals and healthcare drugs segment is estimated to account for the largest market share in 2020. The rising demand for pharmaceutical drugs is expected to drive the demand for the market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=83597438

Market Driver: Increase in demand for fortified food products with health benefits

The demand for microencapsulation is increasing with the growth in demand for functional and fortified food & pharmaceutical products. Microencapsulation provides integration of minerals, vitamins, flavors, essential oils, and other additives in food products to enhance the functional properties of products. The pharmaceutical sector is also greatly influenced by microencapsulation technologies due to the benefits achieved by the manufacturers. Along with the encapsulation of drugs, other active ingredients such as peptides, proteins, and DNA/RNA molecules are also encapsulated in the pharmaceutical sector to meet the market demand for value-added products.

#Microencapsulation Market

0 notes

rohans18 · 1 year ago

Text

Certolizumab Pegol Market Analysis and Forecast to 2029

Global Certolizumab Pegol Market, By Type (Single-dose Vial, Single-dose Prefilled Syringe), Application (Crohn’s disease, Active Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Axial Spondyloarthritis, Others), Dosage Form (Solution, Injection, Others), Route of Administration (Subcutaneous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

The consistent Certolizumab Pegol market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Certolizumab Pegol market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Some of the major players operating in the certolizumab pegol market are UCB S.A., LGM Pharma, ADM, BASF SE, Cargill Incorporated, Land O'Lakes, Inc., Dallas Keith, Agridyne LLC, Ridley Corporation Limited, and Liquid Feeds Inc., among others.

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-certolizumab-pegol-market

One of the principal objectives of a high-ranking Certolizumab Pegol industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Certolizumab Pegol market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Certolizumab Pegol market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Certolizumab Pegol Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

0 notes